Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel

BJU International

Volumn 114, Issue 6, 2014, Pages E11-E17

  Nuhn, Philipp ^a   Vaghasia, Ajay M ^a   Goyal, Jatinder ^a   Zhou, Xian C ^a   Carducci, Michael A ^a   Eisenberger, Mario A ^a   Antonarakis, Emmanuel S ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

chemotherapy; docetaxel; metastatic castration resistant prostate cancer; neutrophil to lymphocyte ratio; overall survival; prostate cancer

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BISPHOSPHONIC ACID DERIVATIVE; DOCETAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE METASTASIS; CANCER SURGERY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CAUCASIAN; CONTROLLED STUDY; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; ADENOCARCINOMA; BLOOD; BONE TUMOR; CYTOLOGY; KAPLAN MEIER METHOD; LEUKOCYTE COUNT; LYMPHOCYTE; MIDDLE AGED; MORTALITY; NEUTROPHIL; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; LYMPHATIC METASTASIS; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS;

EID: 84920124479     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12531     Document Type: Article

References (38)

1. Tannock IF, de Wit R, Berry WR, etal. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512
2. Petrylak DP, Tangen CM, Hussain MH, etal. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520
3. Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ,. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. Clin Oncol (R Coll Radiol) 2013; 25: 406-430
4. de Bono JS, Logothetis CJ, Molina A, etal. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
5. de Bono JS, Oudard S, Ozguroglu M, etal. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154
6. Sonpavde G, Attard G, Bellmunt J, etal. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. Eur Urol 2011; 60: 270-278
7. Mottet N, Bellmunt J, Bolla M, etal. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 572-583
8. Beltran H, Beer TM, Carducci MA, etal. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol 2011; 60: 279-290
9. Kantoff PW, Higano CS, Shore ND, etal. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422
10. Antonarakis ES, Armstrong AJ,. Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2011; 14: 206-218
11. Antonarakis ES, Eisenberger MA,. Expanding treatment options for metastatic prostate cancer. N Engl J Med 2011; 364: 2055-2058
12. Joniau S, Abrahamsson PA, Bellmunt J, etal. Current vaccination strategies for prostate cancer. Eur Urol 2012; 61: 290-306
13. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674
14. Emrich LJ, Priore RL, Murphy GP, Brady MF,. Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 1985; 45: 5173-5179
15. Halabi S, Small EJ, Kantoff PW, etal. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232-1237
16. Smaletz O, Scher HI, Small EJ, etal. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20: 3972-3982
17. Halazun KJ, Aldoori A, Malik HZ, etal. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol 2008; 34: 55-60
18. Keizman D, Ish-Shalom M, Huang P, etal. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 2012; 48: 202-208
19. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ,. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005; 91: 181-184
20. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E,. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009; 137: 425-428
21. Chua W, Charles KA, Baracos VE, Clarke SJ,. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011; 104: 1288-1295
22. Roxburgh CS, McMillan DC,. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010; 6: 149-163
23. Gabay C, Kushner I,. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454
24. Scher HI, Halabi S, Tannock I, etal. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159
25. Goyal J, Nuhn P, Huang P, etal. The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer. BJU Int 2012; 110: E575-582
26. Dinse GE, Lagakos SW,. Nonparametric estimation of lifetime and disease onset distributions from incomplete observations. Biometrics 1982; 38: 921-932
27. Shafique K, Proctor MJ, McMillan DC, Qureshi K, Leung H, Morrison DS,. Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis 2012; 15: 195-201
28. Rashid F, Waraich N, Bhatti I, etal. A pre-operative elevated neutrophil: lymphocyte ratio does not predict survival from oesophageal cancer resection. World J Surg Oncol 2010; 8: 1
29. Azab B, Bhatt VR, Phookan J, etal. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol 2012; 19: 217-224
30. Santoni M, De Giorgi U, Iacovelli R, etal. Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. Br J Cancer 2013; 109: 1755-1759
31. de Martino M, Pantuck AJ, Hofbauer S, etal. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol 2013; 190: 1999-2004
32. Krane LS, Richards KA, Kader AK, Davis R, Balaji KC, Hemal AK,. Preoperative neutrophil/lymphocyte ratio predicts overall survival and extravesical disease in patients undergoing radical cystectomy. J Endourol 2013; 27: 1046-1050
33. Rochet NM, Kottschade LA, Grotz TE, Porrata LF, Markovic SN,. The prognostic role of the preoperative absolute lymphocyte count and absolute monocyte count in patients with resected advanced melanoma. Am J Clin Oncol 2013; doi: 10.1097/COC.0b013e31829b5605 [Epub ahead of print]
34. Ito M, Saito K, Yasuda Y, etal. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel. Urology 2011; 78: 1131-1135
35. Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ,. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 2012; 107: 695-699
36. Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M,. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2010; 16: 203-211
37. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M,. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007; 13: 6396-6403
38. Pond GR, Berry WR, Galsky MD, Wood BA, Leopold L, Sonpavde G,. Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2012; 10: 239-245